An interventional study of Decision tree for initiating treatment in Fabry Disease, sponsored by University Hospital, Bordeaux. Not yet recruiting at 12 sites in France. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Other
Females with Fabry disease are characterized by variable phenotypes regarding time of onset, severity of symptoms and progression of disease due to the random inactivation of X chromosome leading to a cellular mosaic of mutated and wild genotypes.
Left ventricular hypertrophy (LVH) is a relatively late manifestation, appearing typically after the third decade in men and the fourth decade in women. Cardiac involvement progresses throughout life in Fabry females and is the first cause of death but in contrast to males, the loss of myocardial function and the development of fibrosis do not necessarily require myocardial hypertrophy in female with FD.
The presence of overt LVH and myocardial fibrosis has been shown to negatively affect treatment outcome, suggesting the importance of early initiation of treatment.
Multiparametric cardiac magnetic resonance (CMR) is able to detect sphingolipid infiltration by identifying a pre-LVH phase of cardiac FD defined by a low myocardial native T1, occurring in up to 60% of FD patients, with a concomitant slight elevated LV ejection fraction and electrocardiographic (ECG) changes. Low myocardial T1 values are independently associated with FD progression and are risk factors for clinical worsening.
Normal native T1 value is known to be higher in healthy young women than in men but prevalence of low native T1 in Fabry females has not been correctly assessed so far.
Treating Fabry females at the appropriate time is still a major issue and remains questionable as therapeutic and financial burden has to be balanced with severity status.
However, low native myocardial T1 in CMR is an early marker of cardiac impairment in FD that could justify adapting the therapeutic initiation notably in women. This is of paramount importance as early treatment may provide more benefit before occurrence of irreversible lesions such as LVH and fibrosis.
The aim of the study is to estimate the potential therapeutic impact of a non-invasive Cardiac Magnetic Resonance imaging to detect low native myocardial T1 in non-treated nonhypertrophic Fabry females
246 studies on the registry are indexed under Fabry Disease; 56 are open to participants now.
This study's planned enrollment of 60 is above the median of 22 across 108 interventional studies indexed under Fabry Disease.
Browse Fabry Disease studies →University Hospital, Bordeaux is the lead sponsor of 803 studies on the registry; 194 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Contraindication to gadolinium-based contrast agent (GBCA) that include
Potential therapeutic impact of CMR myocardial native T1
Other: Decision tree for initiating treatment
1. Cardiac Magnetic Resonance imaging to detect low native myocardial T1 2. National centralised expert committee to determine therapeutic indications 3. Recommendations forwarded to the local expert committee 4/ Local expert committee decision ( to start or not a specific therapy) 5/ Patiente decision
Proportion of non-treated non-hypertrophic Fabry females for whom the indication for specific Fabry therapy (ERT or chaperone) is modified (i.e. established) based on additional information provided by low native myocardial T1 value.
A centralized expert committee will review all participant data and establish indication for specific Fabry therapy without then with CMR low native T1 value. First, indication for Fabry therapy will be established based on usual follow-up clinical and biological data. Then, CMR parameters will be displayed and change in indication for therapy will be collected.
Time frame: Month 12
Association of low native T1 value with phenotype
Time frame: Inclusion visit
Association of low native T1 value with genotype
Time frame: Inclusion visit
Association of low native T1 value with cardiac status
Time frame: Inclusion visit
Disease progression
Time frame: Between inclusion visit and visit M60
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →